CME: Hemophilia A - Making It Personal: A Patient Experience

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Hemophilia A - Making It Personal: A Patient Experience

Hemophilia A - Making It Personal: A Patient Experience
Review real-world experiences of a patient with hemophilia A, including perspectives from both patient and physician.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Hemophilia A is a rare bleeding disorder caused by deficiency of clotting factor VIII (FVIII). The current standard of care for patients with severe hemophilia A centers on replacement therapy with FVIII concentrate, either on demand when bleeding occurs or prophylactically (replacement therapy). Potential complications from replacement therapy include the development of inhibitory antibodies that attack the clotting factor in approximately one-fourth of patients and viral infections from human clotting factors. Moreover, traditional clotting factor replacement formulations require frequent and time-consuming administration, which in turn has limited use of prophylactic regimens to maintain adequate levels of clotting factor activity.

    In the past several years, new therapies have become available that have the potential to dramatically alter the approach to chronic disease management for the first time in three decades. These new agents offer the opportunity to improve the frequency and convenience of replacement therapy, while achieving an unprecedented degree of protection over time. Furthermore, agents that eliminate use of clotting factor entirely, including factor VIII (FVIII) mimetics and drugs aimed at rebalancing the coagulation cascade via antithrombin, may be useful not only in overcoming inhibitors, but also in preventing their formation.

    This activity features a patient with hemophilia A expressing his real-world experiences throughout his treatment journey. The patient shares his story with regards to diagnosis, treatment challenges, impact on quality of life and how they have overcome obstacles living with hemophilia A.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Evaluate/incorporate new agents into clinical decision-making for the treatment of hemophilia.
    • Understand the long-term importance of prophylaxis in moderate-to-severe hemophilia A and weigh personalized approaches to prophylactic regimens.
    • Apply principles of shared decision-making to enlist patients in management of their disease.
  • Target Audience

    This activity is intended for hemophilia treatment center hematologists, hemophilia specialists, nurses, fellows, pharmacists, and other members of the hemophilia collaborative care team.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Robert Mocharnuk, MD

    Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.

    David Kirschner

    David Kirschner has nothing to disclose.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

    The following AXIS planners and managers, Jocelyn Timko, BS hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Linda Gracie-King, MS, reports her spouse has a financial interest/relationship or affiliation in the form of Common stock:Exelixis. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.

  • Continuing Medical Education

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AXIS Contact Information

    For information about the certification of this activity, please contact AXIS at


  • Provided by

  • Commercial Support

    Supported by an educational grant from Genentech.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio


Programs 12/14/19